1 / 6

Alzheimer’s Disease Pipeline Analysis -Clinical Trials Review, Pipeline Products by Stage of Development & Market anal

According to a new research report Alzheimer’s Disease Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Alzheimer’s disease currently exhibits a pipeline with 89 active drug candidates.

NidhiNehani
Télécharger la présentation

Alzheimer’s Disease Pipeline Analysis -Clinical Trials Review, Pipeline Products by Stage of Development & Market anal

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Alzheimer’s Disease Pipeline to Witness Large R&D Investment in the Coming Years

  2. Alzheimer’s Disease Pipeline Analysis According to a new research report “Alzheimer’s Disease Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Alzheimer’s disease currently exhibits a pipeline with 89 active drug candidates. Alzheimer’s disease pipeline offers novel therapeutic targets for the treatment of Alzheimer’s disease The study analyzed that the Alzheimer’s disease pipeline comprises 89 drug candidates in different stages of development. Browse Report Overview at:https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis

  3. Alzheimer’s Disease Pipeline Analysis Insights on pipeline segments As per the findings of the research, majority of the active drug candidates of Alzheimer’s disease pipeline are being developed to be administered by oral route. SupraAntigen technology platform for Alzheimer’s disease drug development AC Immune, Ltd. is using SupraAntigen technology platform for the development of Crenezumab, ACI-24 and ACI-35 for Alzheimer's disease. This technology is used to produce conformation specific antibodies and is used to create products for active immunization (vaccines) and passive immunization (antibodies).

  4. Alzheimer’s Disease Pipeline Analysis Major companies collaborate for the development of Alzheimer’s disease pipeline The research finds that different companies have collaborated for the development of Alzheimer’s disease pipeline. In March 2014, Eisai Co., Ltd. and Biogen Idec collaborated to develop and commercialize two of Eisai's clinical candidates, E2609 and BAN2401, for Alzheimer’s disease. Some of the key players developing drugs for Alzheimer’s disease are Eli Lilly and Company, Genentech, Inc., Eisai Co., Ltd., and others.

  5. Alzheimer’s Disease Pipeline Analysis Download report sample at: https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related